Composed of the antivirals nirmatrelvir and ritonavir, Paxlovid was incorporated into the treatment of patients with Covid-19 in the Unified Health System (SUS) last Friday (6), announced the Ministry of Health. To prevent hospitalizations and deaths, the drug is recommended for those who have mild to moderate Covid-19.
The emergency use of the drug was approved by the National Health Surveillance Agency (Anvisa) on March 30. With the publication in the Official Gazette of the Union, the Ministry of Health will now have 180 days to make the treatment available in the public health system.
+ Covid-19: use of the drug Paxlovid by SUS goes to public consultation
+ Paxlovid: understand how the Pfizer drug against Covid-19 works
Paxlovid will be given to immunocompromised or elderly patients over the age of 65. It is used orally and indicated for non-hospitalized patients.
While nirmatrelvir prevents viral reproduction in the body, ritonavir inhibits the action of an enzyme that degrades the first compound of the antiviral. As a result, nirmatrelvir remains in the bloodstream longer, which enhances its effect.
Ritonavir is a drug that was already used to treat the HIV virus. Paxlovid was developed by Pfizer.-BioNTech.